Annual report pursuant to Section 13 and 15(d)

Income Taxes (Details) - Schedule of deferred tax assets and liabilities

v3.23.1
Income Taxes (Details) - Schedule of deferred tax assets and liabilities - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Deferred tax assets:    
Net operating losses carry forward $ 44,233 $ 36,405
Share-based compensation 1,334 1,213
Research and development/orphan drug credits 17,247 14,536
Capitalized research and development expenses 13,210 10,426
Others 69 19
Less: valuation allowance (76,093) (62,599)
Deferred tax assets, net